Awaiting development: Guidance and quality standards

Showing 281 to 290 of 338

Guidance and quality standards awaiting development
Title	Type
Supporting independent living and preventing isolation in adults of working age with social care needs	Quality standard
Surgical Mesh for ventral hernias	Health technology evaluation
Surovatamig for treating relapsed or refractory B-cell acute lymphoblastic leukaemia after 2 or more lines of treatment in people 12 years and over [ID6630]	Technology appraisal guidance
Surovatamig for treating relapsed or refractory diffuse large B-cell lymphoma after 2 or more lines of treatment [ID6631]	Technology appraisal guidance
Talazoparib with enzalutamide for untreated hormone-sensitive metastatic prostate cancer with a homologous recombination repair mutation [ID6460]	Technology appraisal guidance
Talquetamab with daratumumab for treating relapsed or refractory multiple myeloma after 1 or more lines of treatment including a proteasome inhibitor and lenalidomide [ID6625]	Technology appraisal guidance
Talquetamab with pomalidomide or teclistamab for treating relapsed or refractory multiple myeloma after 1 or more treatments including an anti-CD38 antibody and lenalidomide [ID6629]	Technology appraisal guidance
Tarlatamamb for treating small-cell lung cancer that has progressed after platinum-based chemotherapy [ID6617]	Technology appraisal guidance
Tasimelteon for treating sleep disturbance associated with Smith-Magenis syndrome [TSID12191]	Technology appraisal guidance
Technologies to support home monitoring of vision change in macular disease	Health technology evaluation